Company / Current Assets
Seres Therapeutics, Inc. Current Assets History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$49.4M
FY2025
5-year range
$49.4M / $303.6M
FY2021-FY2025
Trend
-74.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $195M to $49M over the past 3 years.
Based on SEC 10-K filings.
$49M in FY2025 with a 10-year CAGR of -13.4%.
Declined from $195M to $49M over the past 3 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -36.7%
- 5-Year CAGR
- -28.7%
- 10-Year CAGR
- -13.4%
Key checks
Key Insights
- 5-year CAGR of -28.7%, indicating a declining trend.
- In FY2025, current assets decreased 74.6% year-over-year.
- Peak current assets was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $49.4M | -74.6% |
| FY2023 | $194.8M | +0.0% |
| FY2022 | $194.8M | -35.9% |
| FY2021 | $303.6M | +13.0% |
| FY2020 | $268.8M | +168.3% |
| FY2019 | $100.2M | +8.1% |
| FY2018 | $92.7M | -40.2% |
| FY2017 | $155.1M | -21.8% |
| FY2016 | $198.4M | -4.5% |
| FY2015 | $207.6M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026